The Effect of Interpersonal Relationships Psychotherapy on Breast Cancer Patients

August 31, 2025 updated by: Koç University

The Effect of Interpersonal Relationships Psychotherapy on Depression, Emotion Regulation and Social Support Levels in Breast Cancer Patients With Depression Risk: A Randomized Controlled Study

This study is planned to examine the effect of Interpersonal Relationship Psychotherapy on depression, interpersonal emotion regulation and multidimensional perceived social support levels of breast cancer patients with depression risk.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

There are not enough studies showing the effect of IPT, which is an evidence-based psychotherapy that works on problem areas such as role change that may occur with the disease and provides support for recognizing and using social support mechanisms, on cancer patients. This study is thought to make a significant contribution to the literature, especially in terms of making family support, which has an important place in social support systems, available to patients, intervening in interpersonal emotion regulation problems that may occur in patients and affecting depression levels.

Study Type

Interventional

Enrollment (Actual)

42

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey (Türkiye)
    • Nursing Department
      • Istanbul, Nursing Department, Turkey (Türkiye), 34020
        • Koc University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Includes Criteria

  • Ability to communicate in Turkish
  • Diagnosed with Stage-II and Stage-III breast cancer
  • Continuing outpatient treatment
  • Four points on the Primary Care Depression Screening Scale
  • Internet connection
  • Has a phone that can use the zoom app to continue conversations to be
  • To be able to use the Zoom app

Exclusion Criteria

  • Being a pediatric oncology/hematology patient
  • Diagnosed with stage -IV breast cancer
  • Taking psychopharmacological medication
  • To have received KIPT within the last year

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Psychotherapy
IPT will be administered by the researcher who has completed the interpersonal relations psychotherapy training.
Other: PSYCHOTHERAPY
IPT, was prepared by the researcher who completed the interpersonal relations psychotherapy training.The first interview will be conducted face-to-face in the offices of Koç University Faculty of Nursing. Subsequent sessions will be conducted via Zoom according to the availability of the patients included in the study. The day and time of the interviews will be planned according to the availability of the patients before the interviews. A total of 12 interviews are planned to be conducted with a patient for 40-60 minutes each. Interview intervals will be organized as once a week.
Other Names:
  • interpersonal psychotherapy
No Intervention: Observation
Patients in the control group will be asked to complete the post-tests at the same time after the experimental group interviews are completed. However, no intervention will be made to the control group.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Beck Depression Screening Scale for Primary Care
Time Frame: Through study completion, an average of 6 months
Each question has four answers. The lowest possible score is zero and the highest possible score is three. A total maximum score of 21 and a minimum score of zero can be achieved. Depression scores of breast cancer patients are expected to decrease after treatment. It is expected to fall below 4 points.
Through study completion, an average of 6 months
Interpersonal relationships emotion regulation scale
Time Frame: Through study completion, an average of 6 months
The highest score that can be obtained from the scale is 100 and the lowest score is 20. The high score obtained from each sub-dimension of the scale indicates that the individual has the characteristic evaluated by the relevant sub-dimension. Scores obtained from the scale were found to be related to the total score of the Difficulties in Emotion Regulation Scale and also to depression and anxiety.An increase in the interpersonal relations emotion regulation scale score is expected in breast cancer patients after treatment. This increase shows that it has a positive effect on individuals' emotion regulation.
Through study completion, an average of 6 months
Multidimensional Perceived Social Support Scale:
Time Frame: Through study completion, an average of 6 months
The lowest score that can be obtained from the scale is "12" and the highest score is "84". An increase in the total score of the scale means an increase in the level of perceived social support. Social support scores of breast cancer patients are expected to increase after treatment.
Through study completion, an average of 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Koç University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 15, 2024

Primary Completion (Actual)

June 1, 2025

Study Completion (Actual)

July 1, 2025

Study Registration Dates

First Submitted

February 23, 2024

First Submitted That Met QC Criteria

August 8, 2024

First Posted (Actual)

August 9, 2024

Study Record Updates

Last Update Posted (Estimated)

September 8, 2025

Last Update Submitted That Met QC Criteria

August 31, 2025

Last Verified

August 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 0036315

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe